Cargando…
A Retrospective Study of Intrathecal Pemetrexed Combined With Systemic Therapy for Leptomeningeal Metastasis of Lung Cancer
Objective This retrospective study aimed to investigate the clinical features of lung cancer patients with leptomeningeal metastasis (LM) and explore the clinical efficacy and tolerance of intrathecal pemetrexed (IP) combined with systemic antitumor therapy. Methods Thirty-four lung cancer patients...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928347/ https://www.ncbi.nlm.nih.gov/pubmed/35289201 http://dx.doi.org/10.1177/15330338221078429 |
_version_ | 1784670621743972352 |
---|---|
author | Geng, Di Guo, Qianqian Huang, Siyuan Zhang, Huixian Guo, Sanxing Li, Xingya |
author_facet | Geng, Di Guo, Qianqian Huang, Siyuan Zhang, Huixian Guo, Sanxing Li, Xingya |
author_sort | Geng, Di |
collection | PubMed |
description | Objective This retrospective study aimed to investigate the clinical features of lung cancer patients with leptomeningeal metastasis (LM) and explore the clinical efficacy and tolerance of intrathecal pemetrexed (IP) combined with systemic antitumor therapy. Methods Thirty-four lung cancer patients (11 men, 23 women) with LM receiving IP at our hospital were retrospectively reviewed between August 2018 and December 2019. Identified cases showed either positive cerebrospinal fluid cytology or typical findings (leptomeningeal enhancement or ventricle broadening) upon imaging examination. Results Before the diagnosis of LM, 24 (70.6%) patients received EGFR-TKI therapy with or without other agents (antivascular therapy, or chemotherapy), 5 (14.7%) patients received chemotherapy, 1 (2.9%) patient received antivascular therapy, and 3 (8.8%) patients received ALK inhibitors. Fourteen (41.2%) patients did not change the systematic regimen at the beginning of IP, while 20 (58.8%) patients changed to antitumor agents. IP was administered for a median of 3 times (range, 1-12 times). The IP dose was 15, 20, 25, 30, and 40 mg in 8 (23.5%), 21 (58.8%), 2 (5.9%), 2 (5.9%), and 1 (5.9%) patient, respectively. In all IP dose levels, the major adverse events were myelosuppression and elevation of hepatic aminotransferases (EHA). Grade 1/2 myelosuppression occurred in 4 (11.8%) patients. Grade 1/2 EHA also occurred in 4 (11.8%) patients. Grades 3/4 adverse events were not observed. After IP and systematic therapy, the clinical manifestations related to LM in 26 (76.5%) patients improved. In the whole cohort, the median overall survival was 20 months. The median time from the initial IP administration until death or the last follow-up was 3.5 months. Conclusions IP showed controllable toxicity and good efficacy, prolonged the survival time, and improved the quality of life when combined with tailored systemic antitumor therapy in lung cancer patients. |
format | Online Article Text |
id | pubmed-8928347 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-89283472022-03-18 A Retrospective Study of Intrathecal Pemetrexed Combined With Systemic Therapy for Leptomeningeal Metastasis of Lung Cancer Geng, Di Guo, Qianqian Huang, Siyuan Zhang, Huixian Guo, Sanxing Li, Xingya Technol Cancer Res Treat Original Article Objective This retrospective study aimed to investigate the clinical features of lung cancer patients with leptomeningeal metastasis (LM) and explore the clinical efficacy and tolerance of intrathecal pemetrexed (IP) combined with systemic antitumor therapy. Methods Thirty-four lung cancer patients (11 men, 23 women) with LM receiving IP at our hospital were retrospectively reviewed between August 2018 and December 2019. Identified cases showed either positive cerebrospinal fluid cytology or typical findings (leptomeningeal enhancement or ventricle broadening) upon imaging examination. Results Before the diagnosis of LM, 24 (70.6%) patients received EGFR-TKI therapy with or without other agents (antivascular therapy, or chemotherapy), 5 (14.7%) patients received chemotherapy, 1 (2.9%) patient received antivascular therapy, and 3 (8.8%) patients received ALK inhibitors. Fourteen (41.2%) patients did not change the systematic regimen at the beginning of IP, while 20 (58.8%) patients changed to antitumor agents. IP was administered for a median of 3 times (range, 1-12 times). The IP dose was 15, 20, 25, 30, and 40 mg in 8 (23.5%), 21 (58.8%), 2 (5.9%), 2 (5.9%), and 1 (5.9%) patient, respectively. In all IP dose levels, the major adverse events were myelosuppression and elevation of hepatic aminotransferases (EHA). Grade 1/2 myelosuppression occurred in 4 (11.8%) patients. Grade 1/2 EHA also occurred in 4 (11.8%) patients. Grades 3/4 adverse events were not observed. After IP and systematic therapy, the clinical manifestations related to LM in 26 (76.5%) patients improved. In the whole cohort, the median overall survival was 20 months. The median time from the initial IP administration until death or the last follow-up was 3.5 months. Conclusions IP showed controllable toxicity and good efficacy, prolonged the survival time, and improved the quality of life when combined with tailored systemic antitumor therapy in lung cancer patients. SAGE Publications 2022-03-15 /pmc/articles/PMC8928347/ /pubmed/35289201 http://dx.doi.org/10.1177/15330338221078429 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Article Geng, Di Guo, Qianqian Huang, Siyuan Zhang, Huixian Guo, Sanxing Li, Xingya A Retrospective Study of Intrathecal Pemetrexed Combined With Systemic Therapy for Leptomeningeal Metastasis of Lung Cancer |
title | A Retrospective Study of Intrathecal Pemetrexed Combined With Systemic Therapy for Leptomeningeal Metastasis of Lung Cancer |
title_full | A Retrospective Study of Intrathecal Pemetrexed Combined With Systemic Therapy for Leptomeningeal Metastasis of Lung Cancer |
title_fullStr | A Retrospective Study of Intrathecal Pemetrexed Combined With Systemic Therapy for Leptomeningeal Metastasis of Lung Cancer |
title_full_unstemmed | A Retrospective Study of Intrathecal Pemetrexed Combined With Systemic Therapy for Leptomeningeal Metastasis of Lung Cancer |
title_short | A Retrospective Study of Intrathecal Pemetrexed Combined With Systemic Therapy for Leptomeningeal Metastasis of Lung Cancer |
title_sort | retrospective study of intrathecal pemetrexed combined with systemic therapy for leptomeningeal metastasis of lung cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928347/ https://www.ncbi.nlm.nih.gov/pubmed/35289201 http://dx.doi.org/10.1177/15330338221078429 |
work_keys_str_mv | AT gengdi aretrospectivestudyofintrathecalpemetrexedcombinedwithsystemictherapyforleptomeningealmetastasisoflungcancer AT guoqianqian aretrospectivestudyofintrathecalpemetrexedcombinedwithsystemictherapyforleptomeningealmetastasisoflungcancer AT huangsiyuan aretrospectivestudyofintrathecalpemetrexedcombinedwithsystemictherapyforleptomeningealmetastasisoflungcancer AT zhanghuixian aretrospectivestudyofintrathecalpemetrexedcombinedwithsystemictherapyforleptomeningealmetastasisoflungcancer AT guosanxing aretrospectivestudyofintrathecalpemetrexedcombinedwithsystemictherapyforleptomeningealmetastasisoflungcancer AT lixingya aretrospectivestudyofintrathecalpemetrexedcombinedwithsystemictherapyforleptomeningealmetastasisoflungcancer AT gengdi retrospectivestudyofintrathecalpemetrexedcombinedwithsystemictherapyforleptomeningealmetastasisoflungcancer AT guoqianqian retrospectivestudyofintrathecalpemetrexedcombinedwithsystemictherapyforleptomeningealmetastasisoflungcancer AT huangsiyuan retrospectivestudyofintrathecalpemetrexedcombinedwithsystemictherapyforleptomeningealmetastasisoflungcancer AT zhanghuixian retrospectivestudyofintrathecalpemetrexedcombinedwithsystemictherapyforleptomeningealmetastasisoflungcancer AT guosanxing retrospectivestudyofintrathecalpemetrexedcombinedwithsystemictherapyforleptomeningealmetastasisoflungcancer AT lixingya retrospectivestudyofintrathecalpemetrexedcombinedwithsystemictherapyforleptomeningealmetastasisoflungcancer |